• Prescribing Information
  • Medical Information
  • Coverage & Reimbursement

    ACIP Recommended MenB Vaccines Are Covered by Most Insurance Plans

    ACA=Affordable Care Act; ACIP=Advisory Committee on Immunization Practices; VFC=Vaccines for Children.​​​​​​​
    ​​​​​​​

    Coding for TRUMENBA3

    Type

    Code

    CPT®* Product Code

    90621

    CPT Pediatric
    ​​​​​​​Administration Codes

    90460: Administration of a vaccine with counseling
    90471: Administration of a vaccine without counseling

    NDC

    0005-0100-01
    TRUMENBA single dose

    NDC=National Drug Code.
    *CPT is a registered trademark of the American Medical Association.
    ​​​​​​​

    Diagnosis coding for TRUMENBA4

    ICD-10 Diagnosis Code

    Description

    Z23

    Encounter for Immunization

    Note: Additional ICD-10 codes may be needed depending on the type of patient visit and for immunizations administered during inpatient care.

    ICD-10=International Classification of Disorders, 10th Revision
    Pfizer reserves the right to limit orders by package within any given month based on an individual's purchase history. If an order above the allowance is received, Pfizer reserves the right to cancel the excess amount.

    Reach the Pfizer Vaccines Reimbursement Support Services at:

    Telephone: 1-866-744-3198
    Fax: 1-866-744-3303

    Monday through Friday
    8:00 AM-8:00 PM ET




    Benefit investigation​​​​​​​
    ​​​​​​​

    • Verify patient coverage via telephone or fax 
    • ​​​​​​​Most coverage verifications are completed same day (maximum 48 hours)

    Prior authorization support (if needed)
    ​​​​​​​​​​​​​​

    • Identify necessary steps needed to gain valid prior authorization

    Claims denials/appeals support​​​​
    ​​​​​​​​​​​​​​​​​​​​​

    • Gathering of necessary information for health care provider to file an appeal

    Contact your Pfizer Sales Representative or call a Vaccine Specialist at
    1-844-439-2571


    References:
    1. Data on file. Pfizer Inc, New York, NY.
    2. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices. https://www.cdc.gov/vaccines/acip/committee/acip-charter-2016.pdf. Published April 2016. Accessed July 6, 2020.
    3. Trumenba [prescribing information]. Philadelphia, PA: Pfizer Inc; 2019.
    4. Centers for Medicare and Medicaid Services (CMS). ICD-10_CM official guidelines for coding and reporting: FY 2020. CMS website. https://www.cms.gov/Medicare/Coding/ICD10/Downloads/2020-Coding-Guidelines.pdf. Accessed July 9, 2020.

    Support & Order

    • Welcome to TruSupport
    • Ordering & Inventory
    • Coverage & Reimbursement
    • Patient Adherence

    Ordering & Inventory with TruSupport

    Provides multiple convenient options for ordering TRUMENBA​​​​​​

    View the options

    Coverage & Reimbursement with TruSupport

    Streamlines the processes of confirming your patient's coverage for TRUMENBA

    Learn how Pfizer streamlines

    Indication

    • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
    • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis serogroup B strains has not been confirmed
    • Severe allergic reaction after a previous dose of Trumenba is a contraindication
    • Some individuals with altered immunocompetence may have reduced immune responses to Trumenba
    • Persons with certain complement deficiencies and persons receiving treatment that inhibits terminal complement activation (for example, eculizumab) are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B even if they develop antibodies following vaccination with Trumenba
    • As with any vaccine, vaccination with Trumenba may not protect all vaccine recipients against N meningitidis serogroup B infections
    • Syncope (fainting) can occur in association with administration of injectable vaccines, including Trumenba. Procedures should be in place to avoid injury from fainting
    • In clinical studies, the most common solicited adverse reactions in adolescents and young adults were pain at injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%). Nausea was reported in up to 24% of adolescents in early phase studies
    • Sufficient data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
    • Safety and effectiveness have not been established in pregnant women
    • Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age
    • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis serogroup B strains has not been confirmed

    Please see full Prescribing Information.​​​​​​​